ConductScience.org, home

Trial · NCT00763867

Registered outcomes45

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryExercise Capacity, as Determined by Peak Oxygen UptakeChange from Baseline to Week 24
SecondaryExercise Capacity, as Determined by Peak Oxygen UptakeChange from Baseline to Week 12
SecondaryExercise Capacity as Determined by Walk DistanceChange from Baseline to Week 126 Minute Walk Distance
SecondaryComposite Score Reflective of Clinical StatusMeasured at Week 24
Participants ranked sequentially with ranking stratified in one of three tiers based on: 1. Death (lowest tier) The person with the shortest time from randomization to death is given the lowest rank within the tier. 2. Hospitalizations due to cardiovascular or renal causes (middle tier) For patients alive, the ranking within this tier is based on time to hospitalization from randomization date. The person with the first cardiovascular or renal cause hospitalization will be given the lowest rank within the tier. 3. Change in Minnesota Living with Heart Failure Questionnaire (MLWHFQ) from baseline (highest tier) The use of three tiers within the ranking reflects the greater adverse impact of death or cardiovascular hospitalization on clinical status without an arbitrary assignment as to the relative value of these events in relation to changes in quality of life. Rank order: 1-189 (higher values are better)
SecondaryExercise Capacity as Determined by Walk DistanceChange from Baseline to Week 246 minute walk distance
SecondaryCardiopulmonary Exercise Test (CPET) DurationChange from Baseline to Week 12To interpret the CPET Exercise Duration change endpoints, an increase in exercise duration between Baseline and Week 12/Week 24 is considered to be an improvement
SecondaryCardiopulmonary Exercise Test (CPET) DurationChange from Baseline to Week 24To interpret the CPET Exercise Duration change endpoints, an increase in exercise duration between Baseline and Week 12/Week 24 is considered to be an improvement
SecondaryVentilatory Anaerobic ThresholdChange from Baseline to Week 12To interpret the Ventilatory Anaerobic Threshold (VAT) change endpoints, an increase in VAT between Baseline and Week 12/Week 24 is considered to be an improvement
SecondaryVentilatory Anaerobic ThresholdChange from Baseline to Week 24To interpret the Ventilatory Anaerobic Threshold (VAT) change endpoints, an increase in VAT between Baseline and Week 12/Week 24 is considered to be an improvement
SecondaryMinnesota Living With Heart Failure Questionnaire (MLWHFQ)Change from Baseline to Week 12
The MLWHFQ is a self-administered, disease-specific measure of health related quality of life (QOL) that assesses patients perceptions of the influence of heart failure on physical, socioeconomic and psychological aspects of life. Patients respond to 21 items using a six-point response scale (0-5). The total summary score can range from 0-105 with a lower score reflecting better heart failure related QOL. Two sub-scale scores reflect physical (8 items) and emotional (5 items) impairment. Total score: 0 - 105 Physical subscore: 0 - 40 Emotional subscore: 0 - 25
SecondaryMinnesota Living With Heart Failure QuestionnaireChange from Baseline to Week 24
The MLWHFQ is a self-administered, disease-specific measure of health related quality of life (QOL) that assesses patients perceptions of the influence of heart failure on physical, socioeconomic and psychological aspects of life. Patients respond to 21 items using a six-point response scale (0-5). The total summary score can range from 0-105 with a lower score reflecting better heart failure related QOL. Two sub-scale scores reflect physical (8 items) and emotional (5 items) impairment.
OtherMRI Left Ventricular MassChange from Baseline to Week 24A decrease in LV Mass is considered an improvement
OtherMRI Left Ventricular Mass IndexChange from Baseline to Week 24A decrease in Left Ventricular Mass Index is considered an improvement
OtherMRI Left Ventricular End Diastolic VolumeChange from Baseline to Week 24An increase in Left Ventricular End Diastolic Volume is considered an improvement
OtherMRI Left Ventricular End Diastolic Volume IndexChange from Baseline to Week 24An increase in Left Ventricular End Diastolic Volume Index is considered an improvement
OtherMRI Left Ventricular End Systolic Volume IndexChange from Baseline to Week 24An increase in Left Ventricular End Systolic Volume Index is considered an improvement
OtherMRI Left Ventricular Ejection Fraction (LVEF)Change from Baseline to Week 24An increase in LVEF is considered an improvement
OtherEchocardiogram Left Ventricular MassChange from Baseline to Week 24A decrease in Left Ventricular Mass is considered an improvement
OtherMedial Diastolic ElastanceChange from Baseline to Week 24A decrease in Medial Diastolic Elastance is considered an improvement
OtherLateral Diastolic ElastanceChange from Baseline to Week 24A decrease in Lateral Diastolic Elastance is considered an improvement

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00763867/registered